Richard weinshilboum

Adkins Pogue, Andrea (2010) Public Services Librarian B.A., University of New Mexico M.L.I., San Jose State University

According to Richard Weinshilboum, a consultant in Mayo's division of clinical pharmacology and another author on the paper, another key finding was the "critical role" of genetic information provided by a consulting pharmacist. When patients were at significant risk, 60 percent of pharmacist recommendations were immediately accepted …Coimmunoprecipitation identified a series of ERICH3 interacting proteins including clathrin heavy chain which are known to play a role in vesicular function. Immunofluorescence showed ERICH3 colocalization with 5-HT in vesicle-like structures, and ERICH3 knock-out dramatically decreased 5-HT staining in SK-N-SH cells as well as 5-HT ...Mayo Clinic个体化医学中心主任、Mayo Clinic药物基因组学（PGx）计划负责人Richard Weinshilboum教授 回顾了药物基因组学发展历程，且对于Mayo Clinic 常见药物的重点基因及位点做了详尽的介绍。目前Mayo 已将77种药物-基因信息纳入其电子病历，这极大提高了临床诊断的 ...Jun 26, 2023 · Funding support for the PGRN-AMPS study was provided by the National Institute of General Medical Sciences, National Institutes of Health, through the PGRN grant to Principal Investigators R. Weinshilboum and L. Wang (Grant No. U19 GM61388). D. Mrazek served as the Principal Investigator for the PGRN-AMPS study within the Mayo Clinic PGRN program. Dive into the research topics where Richard M Weinshilboum is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles; Pharmacogenetics Medicine & Life Sciences 100%. thiopurine methyltransferase Medicine & Life Sciences 67% ...Contact Dr. Weinshilboum at Mayo Clinic about his pharmacogenomics research to improve the efficacy of drug therapies for the treatment of cancer and psychiatric diseases or for information about opportunities for collaboration or training. Richard Weinshilboum, M.D. Pharmacogenomics Laboratory; Mayo Clinic Gonda Building, Room 19-414 200 First ...Changes in the levels of amino acids and biogenic amines such as histidine, kynurenine, methionine sulfoxide, arginine, citrulline, ornithine, and urea have been implicated in MDD 45-53.Blood lipid changes have also been implicated in the pathophysiology of depression, schizophrenia, and Alzheimer's disease 54-58.Lipids are involved in crucial brain functions, including cell membrane ...

Search 153 grants from Richard Weinshilboum Search 37 grants from Liewei Wang Search grants from Mayo Clinic, RochesterRichard Weinshilboum, M.D. studies pharmacogenomics — the role of inheritance and individual variation in DNA sequence or structure in drug response. The goal is to develop safer and more effective drug therapy to treat diseases that range from cancer to depression.Additional file 1: Figure S1: Characterization and utilization of PDX models generated from both pretreatment biopsies and surgical samples in the BEAUTY study.Figure S2. Representative immunohistochemistry shows the change of subtype from luminal B to triple negative. The histology is depicted using H&E staining and the expression of ER, PR, HER2, and Ki-67 is compared between the ...Duan Liu # 1 , Thanh Thanh Le Nguyen # 1 2 , Huanyao Gao 1 , Huaizhi Huang 1 2 , Daniel C Kim 1 , Brenna Sharp 1 , Zhenqing Ye 3 , Jeong-Heon Lee 4 , Brandon J Coombes 3 , Tamas Ordog 5 6 , Liewei Wang 1 , Joanna M Biernacka 3 7 , Mark A Frye 8 , Richard M Weinshilboum 9He succeeds Richard Weinshilboum, M.D., who provided outstanding leadership as the interim director of the Center for Individualized Medicine following the departure of Keith Stewart, M.B., Ch.B., in 2020. Dr. Weinshilboum played a critical role in advancing the center's 10-year strategic plan in alignment with Mayo Clinic's 2030 strategy, and ...

Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyIntroduction. Advances in genomic sequencing have resulted in opportunities to individualize patient care. The advent of next-generation sequencing has allowed for interrogation of the genome at a significantly reduced cost and may provide the opportunity for some cancer patients to pursue genome-guided therapy by identifying targetable somatic variants [].Richard Weinshilboum, a professor of pharmacology at Mayo Clinic who co-directs the Center for Individualized Medicine's pharmacogenomics program, said his colleagues are now focused on gathering evidence to demonstrate the clinical utility of PGx testing in the population and discover new drug/gene interactions.Protocol recruited 1013 patients and identified variants in CYP2C19, CYP2C9, VKORC1, SLCO1B1, and CYP2D6 that could cause drug-gene interactions with warfarin, clopidogrel,Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011; 364:1144-1153. [PMC free article] [Google Scholar] Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011; 36:87-113. [PMC free article] [Google Scholar]

Kyoka's.

The PGRN-AMPS study was supported by U19 GM61388 and R01 GM28157 (to Drs. Liewei Wang and Richard Weinshilboum). Dr. Bobo’s research has been supported by the National Institute of Mental Health, the Mayo Foundation, and the Brain and Behavior Research Foundation (formerly NARSAD).One Sentence Summary Genomic and epigenomic fine-mapping of ligand-dependent genetic variants unmasks novel disease risk genes ### Competing Interest Statement Drs. Richard Weinshilboum and Liewei Wang are co-founders and stockholders in OneOme, LLC. Other authors declare no conflict of interestsRichard Weinshilboum pronunciation with meanings, synonyms, antonyms, translations, sentences and more Which is the right way to pronounce the cognitive? co-gni-tiveRichard Weinshilboum, M.D., Interim Director, Center for Individualized Medicine, Division Chair -Clinical Pharmacology, Professor of Medicine and Pharmacology. Mat Wiepert, M.S., Section Head, Information Technology, Instructor in Biomedical Informatics University of Illinois MembersOct 8, 2019 · INTRODUCTION. Pharmacogenomics (PGx) examines how variations in an individual’s DNA sequence affect drug metabolism and response, including occurrence of adverse drug events and impact on treatment effectiveness. 1,2 It differs from traditional diagnostic genetic/genomic testing, which looks at the associations between changes in a person’s DNA sequence and diseases. 3 Thus, PGx may ...

Dr. Richard Weinshilboum, MD is an Internal Medicine Specialist in Rochester, MN and has 51 years experience. They graduated from UNIVERSITY OF KANSAS / SCHOOL OF MEDICINE. They currently practice at Practice. Their office is not accepting new patients. Dr. Weinshilboum is board certified in Internal Medicine.INTRODUCTION. Pharmacogenomics (PGx) examines how variations in an individual’s DNA sequence affect drug metabolism and response, including occurrence of adverse drug events and impact on treatment effectiveness. 1,2 It differs from traditional diagnostic genetic/genomic testing, which looks at the associations between changes in a person’s DNA sequence and diseases. 3 Thus, PGx may ...Nie żyje Czesław Hinc. fot. Andrzej Ryfczyński / archiwum. Czesław Hinc to znany artysta który tworzył obrazy w miedzi. Długoletni mieszkaniec Świnoujścia. Zmarł …AU - Weinshilboum, Richard. AU - Biernacka, Joanna M. N1 - Funding Information: The PGRN-AMPS study was supported by U19 GM61388 and R01 GM28157 (to Drs Liewei Wang and Richard Weinshilboum). Dr. Bobo's research has been supported by the National Institute of Mental Health, the Mayo Foundation for Medical Education and Research, and the Brain ...This overview will describe the evolution of germline pharmacogenomic research strategies as we have moved from an era of candidate genes to agnostic genome-wide association studies (GWAS) coupled with the functional and mechanistic pursuit of GWAS signals. Germline pharmacogenomic studies of breast cancer endocrine therapy will be used to ...Richard Weinshilboum Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, MN. Corresponding author: Richard Weinshilboum, [email protected]. Search for other works by this author on: ...Dr. Richard Weinshilboum and Arjun Athreya at ASCPT 2017. Congratulations to Arjun Athreya on his best paper award from BDCAT 2016! Dr. Estrada, the Estrada family, thesis committee and DEPEND members after his final exam. DEPEND members celebrating Homa's Hooding and Commencement ceremony at Prof. Iyer's residence.Additional file 1: Figure S1: Characterization and utilization of PDX models generated from both pretreatment biopsies and surgical samples in the BEAUTY study.Figure S2. Representative immunohistochemistry shows the change of subtype from luminal B to triple negative. The histology is depicted using H&E staining and the expression of ER, PR, HER2, and Ki-67 is compared between the ...Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537. ... Liewei Wang MD, PhD & Richard Weinshilboum MD. Authors. Ye Zhu MD, PhD. View author publications.Richard Weinshilboum, M.D., Interim Director, Center for Individualized Medicine, Division Chair -Clinical Pharmacology, Professor of Medicine and Pharmacology.Below are recordings of the Scientific Seminars in 2019. The Scientific Seminar series provides presenters with planning and travel support. If you are interested in inviting a speaker or presenting your research, contact Casper Bendixsen, Ph.D., chairman of the Scientific Seminar series or call 715-387-9410.

Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data

Richard Weinshilboum, a professor of pharmacology at Mayo Clinic who co-directs the Center for Individualized Medicine's pharmacogenomics program, said his colleagues are now focused on gathering evidence to demonstrate the clinical utility of PGx testing in the population and discover new drug/gene interactions.The team, led by researchers Liewei Wang, Arjun Athreya, and Richard Weinshilboum, says that the concept of using computers to predict drug treatment outcomes was initially used for individuals ...Liewei Wang 1 , Bianca Thomae, Bruce Eckloff, Eric Wieben, Richard Weinshilboum. Affiliation 1 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, USA. PMID: 12167489 DOI: 10.1016 ...Pharmacogenomics in Practice. Pharmacogenomics is an important aspect of clinical genomics that is touching an increasingly large number of patients. That is because pharmacogenomic testing is being implemented into clinical care at an increasing pace—initially primarily within academic medical centers, but also across healthcare systems.Abstract. INTRODUCTIONPatient derived xenografts (PDX) may better reflect individual patient (pt) tumor biology; however, the feasibility of collecting PDX from percutaneous tumor biopsies (PTB) in the neoadjuvant setting is unknown. Furthermore, drug response phenotypes observed in PDX have not been prospectively compared to the corresponding pt clinical outcomes.METHODSThe Breast Cancer ...Dr. Lazaridis succeeds Richard Weinshilboum, M.D., who has provided outstanding leadership as the interim director of the Center for Individualized Medicine following the departure of Keith Stewart, M.B., Ch.B., in 2020. Dr. Weinshilboum played a critical role in advancing the center's 10-year strategic plan in alignment with Mayo Clinic's 2030 ...PI Name: Richard Weinshilboum, M.D. Email: [email protected] . Single cell transcriptomics reveals distinct transcriptional response to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder . Ming-Fen Ho, Cheng Zhang. 1, Irene Moon 1, Brandon Coombes 2, Joanna Biernacka , Michelle Skime. 3Weinshilboum reports grants from NIH during the conduct of the study, as well as other support from OneOme LLC outside the submitted work. J.A. Copland III reports other support from Wuxi licensed PDX mouse models outside the submitted Funding Information: work. M.P. Goetz reports other support from Eagle Pharmaceuticals, Lilly, Biovica ...Richard Weinshilboum Mayo Medical School-Mayo Graduate School, Mayo Clinic College of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, …Yuan Ji, Timothy Nelson & Richard Weinshilboum. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. Michelle Skime & Daniel Hall-Flavin.

Ku basketball watch.

Sellards scholarship hall.

In the small-town Kansas of Richard Weinshilboum, M.D.’s childhood, most of the local doctor’s patients received the same treatment when they were sick: a placebo and a comforting dose of the doctor’s hands placed where it hurt.Richard Weinshilboum is a Co-Founder and stockholder in OneOme, LLC, a pharmacogenomics decision support company. ... Goss P.E., Shepherd L.E., Mushiroda T., Kubo M., Wang L., Weinshilboum R.M. TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: …Dec 17, 2021 · “This approach began by developing tools to predict drug treatment outcomes in major depressive disorder, but we are delighted to see that it can potentially be applied widely, in this case to the drug therapy of rheumatoid arthritis,” says pharmacogenomics leaders Drs. Wang and Weinshilboum. Biography. Richard Weinshilboum is a Professor of Medicine and Pharmacology. His research focuses on pharmacogenetics and pharmacogenomics, and his studies have resulted in the discovery and characterization of a series of functionally and clinically important genetic polymorphisms and the rapid “translation” of that information into clinical studies designed to test hypotheses with regard ... Education & Training. Massachusetts General Hospital Residency, Internal Medicine, 1971 - 1972. Massachusetts General Hospital Residency, Internal Medicine, 1967 - 1969. University of Kansas School of Medicine Class of 1967."The Human Genome Project was not a race to the finish line, it was a race to the starting line," says Richard Weinshilboum, M.D., interim director for the Center for Individualized Medicine. ... to treat disease and eventually to prevent disease," says Dr. Weinshilboum. ...IV, V, and VII; Prof. Richard Gumport from University of Illi-nois conducted it for Classes IV, V, VII, and VIII; and Prof. Woodland Hastings from Harvard did it for Class VIII. It is fair to say that the fate of many Chinese students was determined by these interviews. It is also sad to say that Profs. ManfredResearch collaborators of Dr. Weinshilboum's Pharmacogenomics Laboratory at Mayo Clinic's campus in Minnesota.Adkins Pogue, Andrea (2010) Public Services Librarian B.A., University of New Mexico M.L.I., San Jose State UniversityDr. Richard Weinshilboum, director of Mayo Clinic's Pharmacogenomics Program. Patients with metastatic lung, breast or brain cancers and patients with melanoma or leukemia now have new treatments available to them. Genome or exome sequencing provides a "molecular diagnosis" that allows physicians to tailor treatments specifically for the ...(Modified from Weinshilboum and Sladek 50 with the permission of the publisher.) Panel B shows the human TPMT gene. TPMT*1 is the most common allele, and TPMT*3A is the most common variant allele ... 1 មេសា 2001 ... Thiopurine Pharmacogenetics: Clinical and Molecular Studies of Thiopurine Methyltransferase. Richard Weinshilboum. Drug Metabolism and ... ….

Ming-Fen Ho 1 , Cheng Zhang 2 , Irene Moon 2 , Lixuan Wei 2 , Brandon Coombes 3 , Joanna Biernacka 3 , Michelle Skime 4 , Doo-Sup Choi 2 , Mark Frye 4 , Kristen Schmidt 5 , Kate Gliske 5 , Jacqueline Braughton 5 , Quyen Ngo 5 , Cedric Skillon 5 , Marvin Seppala 5 , Tyler Oesterle 4 , Victor Karpyak 4 , Hu Li 2 , Richard Weinshilboum 6Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events Ye Zhu, MD, PhD; Guilherme S. Lopes, PhD; Suzette J ...Charlotte Amalie, VI (00802) Today. Partly cloudy. High near 90F. Winds ENE at 10 to 15 mph..Richard Weinshilboum, M.D. "This area of clinical genomics applies to every medical specialty and will eventually touch the care of every patient. While we are just at the beginning of understanding how genomics affect drug response, research has shown the benefit of using pharmacogenomics in clinical care.ROCHESTER, Minn. — Experts in individualized medicine — the concept of shaping health care based on lifestyle, environment and genetic code — will be in Rochester Sept. 12-13 to present how the newest discoveries can be applied to personalized health care. These experts will be available for interviews at Individualizing Medicine 2018: Advancing Care Through […]Drs L Wang and RM Weinshilboum are co-founders and stockholders in OneOme. Dr. WV Bobo's research has been supported by the National Institute of Mental Health, the Agency for Healthcare Quality and Research, the National Science Foundation, the Myocarditis Foundation, and the Mayo Foundation for Medical Education and Research.Jiawei Han, Saurabh Sinha, Jun S. Song, Richard M. Weinshilboum: BD2K-LINCS DCIC: Icahn School of Medicine at Mount Sinai: Avi Ma'ayan, Mario Medvedovic, Stephan C. Schurer: Mobile Sensor Data to Knowledge (MD2K) University of Memphis: Santosh Kumar: Mobilize: Stanford University: Scott Delp: Center for Big Data in Translational GenomicsTogether, our data indicate that overexpression of FOXA1 may play a pivotal role in regulating immune coldness by modulating IFN response gene expression in PCa and BCa. FOXA1 levels inversely correlate with IFN signaling gene expression in prostate (PCa) and breast cancer (BCa). ( A) GSEA enrichment plots show the inverse correlation between ...Richard Weinshilboum Major depressive disorder (MDD) is the most common psychiatric illness worldwide, and it displays a striking sex-dependent difference in incidence, with two thirds of MDD ... Richard weinshilboum, Send reprint requests to: Dr. Richard Weinshilboum, Dept. of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905-0001. E-mail: weinshilboum.richard{at}mayo.edu., "The Human Genome Project was not a race to the finish line, it was a race to the starting line," says Richard Weinshilboum, M.D., interim director for the Center for Individualized Medicine. ... to treat disease and eventually to prevent disease," says Dr. Weinshilboum. ..., Residencies and fellowships; 300+ GME programs in all medical and surgical specialties; Health sciences education; 140+ programs, internships, and rotations in 50 health sciences fields, Funding support for the PGRN-AMPS study was provided by the National Institute of General Medical Sciences, National Institutes of Health, through the PGRN grant to Principal Investigators R. Weinshilboum and L. Wang (Grant No. U19 GM61388). D. Mrazek served as the Principal Investigator for the PGRN-AMPS study within the Mayo Clinic PGRN program., Background. It is estimated that over 2.2 million breast cancer cases occurred worldwide in 2020, representing 1 in 4 cancers diagnosed among women [1, 2].The molecular classification of breast cancer is based on human epidermal growth factor receptor-2 (HER2) gene amplification and the expression of sex hormones, estrogen, and progesterone …, Richard Weinshilboum, M.D. *AskMayoExpert is an online tool available to Mayo Clinic and Mayo Clinic Care Network physicians. Join our community. Get the latest news from the Center for Individualized Medicine. Visit our blog, Facebook, LinkedIn or Twitter at @MayoClinicCIM., Abstract. INTRODUCTIONPatient derived xenografts (PDX) may better reflect individual patient (pt) tumor biology; however, the feasibility of collecting PDX from percutaneous tumor biopsies (PTB) in the neoadjuvant setting is unknown. Furthermore, drug response phenotypes observed in PDX have not been prospectively compared to the corresponding pt clinical outcomes.METHODSThe Breast Cancer ..., Dr Weinshilboum reported receiving grants from NIH and NHLBI and that he is cofounder of, and stockholder in, OneOme LLC. Dr Welsh reported receiving personal fees from Mayo Clinic; receiving grants from AstraZeneca and Pfizer; and receiving grants and personal fees from Bayer and Boerhinger Ingelheim., Richard Weinshilboum. View author publications. You can also search for this author in PubMed Google Scholar ..., Richard Weinshilboum. View author publications. You can also search for this author in PubMed Google Scholar ..., Richard Weinshilboum Background and purpose: Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic ... , He succeeds Richard Weinshilboum, M.D., who provided outstanding leadership as the interim director of the Center for Individualized Medicine following the departure of Keith Stewart, M.B., Ch.B., in 2020. Dr. Weinshilboum played a critical role in advancing the center's 10-year strategic plan in alignment with Mayo Clinic's 2030 strategy, and ..., While some would like to drape the mantle "The father of pharmacogenomics" on Richard Weinshilboum, M.D., the scientist parries: "The only thing that I'm father of is my two children.". Either way, no one can argue that this charming, self-deprecating, diminutive gentleman is a titan in his field; and a giant reason Mayo can claim three decades of leadership in propelling this exploding ..., Richard Weinshilboum. Clinical Pharmacology Unit, Department of Pharmacology, Mayo Clinic/Mayo Foundation, Rochester, MN 55905, USA. Search for more papers by this author, Adkins Pogue, Andrea (2010) Public Services Librarian B.A., University of New Mexico M.L.I., San Jose State University, Welcome to the Thiopurine methyltransferase (TPMT) nomenclature website. This site has initially been set up by Dr Malin Lindqvist Appell, Linkoping University, Sweden and Dr Sally Coulthard, Newcastle …, Richard Weinshilboum, M.D., is chair of the Division of Clinical Pharmacology and a professor of medicine and pharmacology at Mayo Clinic College of Medicine and Science. Contact Get in touch with the Department of Molecular Pharmacology and Experimental Therapeutics about ongoing research projects and opportunities for collaboration or training., Background/Purpose: Methotrexate (MTX) is the most common anchor drug for rheumatoid arthritis (RA), but the risk of missing the opportunity for early effective treatment with alternative medications is substantial given the delayed onset of MTX action and 30-40% inadequate response rate. There is a compelling need to accurately predict MTX response before treatment initiation, in order to ..., Richard Weinshilboum Estrogens are used as drugs and estrogen exposure is a risk factor for hormone-dependent diseases such as breast cancer. Sulfate conjugation is an important pathway for ..., Bielinski SJ, Olson JE, Pathak J, Weinshilboum RM, Wang L, Lyke KJ, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014; 89 (1):25-33., Weinshilboum and Sladek reported trimodality for level of red cell TPMT among 298 randomly selected Caucasians: 88.6% had high enzyme activity, 11.1% had intermediate activity, and 0.3% had undetectable activity. This distribution conformed to Hardy–Weinberg expectations for a pair of autosomal codominant alleles for low and high activity ..., Introduction. Betaine-homocysteine methyltransferase (BHMT, EC 2.1.1.5) catalyzes a key reaction at the convergence of the folate and the methionine cycles (Fig. 1).BHMT is a zinc-dependent cytosolic enzyme that is highly expressed in the human liver, kidney and lens of the eye [1; 2].It catalyzes one of two major homocysteine remethylation reactions, the transfer of a methyl group from ..., Kjeld Schmiegelow, 1, 2 Ibrahim Al-Modhwahi, 2 Mette Klarskov Andersen, 3 Mikael Behrendtz, 4 Erik Forestier, 5 Henrik Hasle, 6 Mats Heyman, 7 Jon Kristinsson, 8 Jacob Nersting, 2 Randi Nygaard, 9 Anne Louise Svendsen, 10 Kim Vettenranta, 11 and Richard Weinshilboum 12, for the Nordic Society for Paediatric Haematology and Oncology, Richard Weinshilboum The influence of genetic variations in SLC6A4 (serotonin transporter gene) on citalopram treatment of depression using the Sequenced Treatment to Relieve Depression (STAR*D ..., Richard Weinshilboum, M.D., is chair of the Division of Clinical Pharmacology and a professor of medicine and pharmacology at Mayo Clinic College of Medicine and Science. Contact Get in touch with the Department of Molecular Pharmacology and Experimental Therapeutics about ongoing research projects and opportunities for collaboration or training., Introduction. Annually, 700,000 people die by suicide worldwide, and there are 10-20 times as many non-fatal suicide attempts (Hannah et al., 2015; WHO, 2021).Patients with major depressive disorder (MDD) and prior suicide attempt(s) demonstrate lower antidepressant remission and response rates and increased antidepressant intolerance compared to those with no history of suicide attempt ..., Additionally, in collaboration with Lynn C. Hartmann, M.D., Ellen L. Goode, Ph.D., and Richard Weinshilboum, M.D., Dr. Wahner Hendrickson is working to evaluate and validate the association between inherited variation throughout the genome and time to progression as well as grade of peripheral neuropathy among over 5,000 epithelial ovarian ..., Caption: Richard Weinshilboum, MD, studies pharmacogenomics—the role of inheritance and individual variation in DNA sequence or structure in drug response. The goal is to develop safer and more effective drug therapy to treat diseases ranging from cancer to depression. , Richard Weinshilboum Sulfate conjugation catalyzed by phenol sulfotransferase (PST) is the major metabolic pathway for methyldopa. Methyldopa is also O-methylated in a reaction catalyzed by ..., Send reprint requests to: Dr. Richard Weinshilboum, Dept. of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905-0001. E-mail: weinshilboum.richard{at}mayo.edu., A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care pr, Richard Weinshilboum Sulfate conjugation catalyzed by sulfotransferase (SULT) enzymes is an important pathway in the biotransformation of many drugs, other xenobiotics, neurotransmitters, and ..., View M. Richard Weinshilboum's profile on LinkedIn, the world's largest professional community. M. has 1 job listed on their profile. See the complete profile on LinkedIn and discover M.'s ...